1stOncology™: Cancer Intelligence Service – Page 28 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CraniUS Therapeutics Closes $20 Million Series B Round to Advance NeuroPASS™ Platform Towards Future Commercialization

On January 28, 2026 CraniUS Therapeutics LLC, a privately held neurotechnology company, reported it has raised $20 million in Series B financing to accelerate development of NeuroPASS, a fully implantable, skull-embedded platform designed to bypass the blood-brain barrier (BBB) and enable targeted drug delivery and monitoring in the brain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

NeuroPASS is being developed as a multi-product platform, with an initial roadmap of three complementary products intended to progressively expand therapeutic capability. Together, these devices are intended to evolve cranial implants from passive reconstructive hardware into an active therapeutic interface capable of supporting long-term outpatient care.

CraniUS Therapeutics was founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon and pioneer of the new surgical field known as Neuroplastic Surgery, who has spent more than 15 years studying and investigating the temporal cranial space as an optimal site for therapeutic delivery. The company was born from a persistent clinical challenge Dr. Gordon encountered in practice: patients with devastating neurological diseases often succumbed not because surgery could not help, but because life-saving medicinal therapies could not reach the brain due to the BBB.

"This is not an incremental advance—it represents a fundamentally new approach to treating neurological disease and brain cancer," said Dr. Gordon, Founder and Executive Chair of CraniUS Therapeutics. "We set out to build a platform that could help address a therapeutic barrier that has limited care for decades."

The Series B financing follows CraniUS’s $20 million Series A round in 2022. The Series B includes $19 million from private investors and $1 million in non-dilutive funding from the State of Maryland, bringing total capital raised to approximately $40 million. The new capital is expected to support operations into 2027 and will support regulatory submissions, manufacturing scale-up and product testing towards future commercialization.

CraniUS holds 15 issued domestic patents supporting its platform and long-term product roadmap, as well as numerous international patents.

"Having led large academic health systems and worked at the intersection of care delivery and innovation, we’ve put robots in operating rooms and AI in radiology suites, but the blood-brain barrier has stubbornly ignored a century of pharmaceutical and medical device innovation, said Dr. Stephen Klasko, a member of the CraniUS board of directors." "NeuroPASS represents exactly the kind of ‘why not?’ thinking that transforms medicine, not incremental improvement, but a fundamental reimagining of how we access the brain."

(Press release, CraniUS, JAN 28, 2026, View Source [SID1234662344])

Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer

On January 28, 2026 Cycle Group Holdings Limited ("Cycle" or "Parent") reported that AT2B, Inc., a Delaware corporation ("Purchaser") and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation ("Applied") for (i) $0.088 per share, net to the seller in cash, without interest, plus (ii) one non-tradeable contingent value right per share.

The offer, which was previously scheduled to expire at one minute following 11:59 p.m., Eastern time, on January 27, 2026 is extended until one minute following 11:59 p.m., Eastern time, on January 28, 2026.

Equiniti Trust Company, LLC, the depositary for the offer, has advised Cycle that, as of 11:59 p.m., Eastern time, on January 27, 2026, approximately 63,684,636 shares (which include 3,735,684 shares subject to guaranteed delivery) have been validly tendered and not properly withdrawn pursuant to the offer, representing approximately 41.29% of the outstanding shares of Applied. Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to this extension.

The offer is being made pursuant to the terms and conditions described in the offer to purchase, filed on December 29, 2025 (together with any amendments and supplements hereto), copies of which are attached to the tender offer statement on Schedule TO filed by Cycle and Purchaser with the US Securities and Exchange Commission, as amended.

The offer is conditioned upon the fulfilment of certain conditions described in Section 15—"Conditions to the Offer" of the offer to purchase, including, but not limited to, the tender of a majority of the then-outstanding shares of Applied’s common stock.

MacKenzie Partners, Inc. is acting as information agent for the offer. Requests for documents and questions regarding the offer may be directed to MacKenzie Partners, Inc by telephone, toll-free at 1-800-322-288. Bankers and Brokers may call at 212-929-5500.

(Press release, Cycle Pharmaceuticals, JAN 28, 2026, View Source [SID1234662343])

Accent Therapeutics to Utilize Inocras’ CancerVision™ and MRDVision™ Platforms in Phase 1/2 ATX-295 Clinical Study

On January 28, 2026 Inocras, a bioinformatics-led company harnessing the power of whole genome data and proprietary analytics to deliver curated insights, reported that Accent Therapeutics will deploy Inocras’ CancerVision and MRDVision whole genome platforms in its first-in-human Phase 1/2 dose-escalation study of ATX-295, a potential best-in-class inhibitor of the KIF18A protein.

Through this collaboration, Inocras’ CancerVision platform is being applied to characterize the detailed genomic status of clinical samples, while MRDVision provides ultra-sensitive monitoring of treatment response during dose escalation. Together, these platforms enable a comprehensive view of tumor dynamics.

"This collaboration marks an inflection point in how whole genome data drives clinical execution," said Jehee Suh, CEO of Inocras. "By deploying our CancerVision and MRDVision platforms, we are empowering Accent’s team with the comprehensive, ultra-sensitive insights needed to accelerate their groundbreaking ATX-295 program. This partnership underscores that whole genome profiling is no longer just for research; it is a critical tool for next-generation drug development."

"Access to a robust, clinically validated, whole-genome cancer profiling platform such as CancerVision has been critical to accelerating translational insights and clinical execution for our ATX-295 program," said Serena Silver, Ph.D., Chief Scientific Officer of Accent Therapeutics. "We are eager to use the insights gained from the Inocras platform to help advance ATX-295 in the clinic."

(Press release, Accent Therapeutics, JAN 28, 2026, View Source [SID1234662342])

Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer

On January 28, 2026 Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, reported that Peter Melnyk has been appointed to President & Chief Executive Officer, effective immediately. Mr. Melnyk succeeds Tim Whitten, who has retired after 13 years of service.

"Peter has spent his career working to bring transformative oncology treatments to patients around the world," said Masa Kobayashi, President & Representative Director of Taiho Pharmaceutical Co., Ltd. "With Peter as President & CEO, we are positioning the company for a successful future to help as many people affected by cancer as possible. We trust Peter to guide TOI’s continued growth and innovation as we pursue our mission to improve the lives of patients with cancer, their families and their caregivers."

"During Tim Whitten’s tenure, TOI launched its first commercial product and has grown from one product in one indication to three products in five indications with a robust pipeline and a bright future," Mr. Kobayashi continued. "The Taiho organization has deep gratitude for Tim’s strong, compassionate leadership and the positive impact that he has made – both within the company and more broadly, in oncology. We thank him for the positive impact he has had on the lives of patients with cancer and wish him well in his retirement."

Mr. Melnyk has more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. Mr. Melnyk joined Taiho Oncology from Alpha Tau Medical, where he was the Chief Commercial Officer and former board member and led the global commercialization efforts for a novel alpha-emitting radiotherapeutic. He was also the CEO of Fortovia Therapeutics and drove the transformation and portfolio expansion in oncology supportive care. In addition, Mr. Melnyk was the Chief Commercial Officer at Novocure, where he built the global commercial infrastructure and launched Optune, a novel medical device for the treatment of glioblastoma.

"I’m deeply honored to be part of Taiho’s next chapter and with my colleagues, continue making a lasting impact for the patients we serve," Mr. Melnyk said. "Together, we will continue to build upon Taiho Oncology’s strong foundation – combining rigorous science, strategic thinking and heartfelt dedication to patients. Thank you to every Taiho team member for your continued commitment to patients and innovation."

(Press release, Taiho, JAN 28, 2026, View Source [SID1234662341])

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

On January 28, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT.

(Press release, Personalis, JAN 28, 2026, View Source [SID1234662340])